Fig. 3From: Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammationOrexin A significantly reduces inflammatory responses in the CNS. The panel shows the mRNA expression of chemokines (i.e., MCP-1 or CCL2 and IP-10 or CXCL10), cytokines (i.e., TNF-Ī±, IL-10, IFN-Ī³ (Th1), IL-17 (Th17), IL-4 (Th2), and TGF-Ī²) and the transcription factor, Foxp3 (Treg-specific) determined by real time RT-PCR in naĆÆve animals and EAE mice (i.e., 15 and 21Ā days after EAE induction in PBS- and OxA-treated mice, nā=ā6/group and nā=ā7/group respectively). *Pā<ā0.05 (Mann-Whitney test, compared to PBS group)Back to article page